Nicox completed the Denali Phase 3 trial for NCX 470, targeting open-angle glaucoma and ocular hypertension. NCX 470 combines ...

Patients express mixed feelings about AI in healthcare, favoring its use for documentation and administrative tasks while ...

Danegaptide is an oral therapy for early treatment of non-proliferative diabetic retinopathy (NPDR) and associated edema.

Through the program, gene therapies are developed to treat patients with retinitis pigmentosa caused by pathogenic variants ...

Perfuse Therapeutics is conducting trials for the treatment for glaucoma and diabetic retinopathy, aiming to restore vision ...

ST-100 shows promise as a fast-acting treatment for dry eye disease, offering rapid relief and unique collagen repair ...

Qlaris Bio to showcase promising data on QLS-111, a novel glaucoma treatment, at the 2025 World Glaucoma Congress, ...

From Nobel laureates to AI-driven research, the Wilmer Eye Institute honors a century of transforming vision science and care ...

PYC Therapeutics advances VP-001 for retinitis pigmentosa, gaining FDA insights for its upcoming registrational trial.

Kodiak Sciences showcases KSI-101, a potential new treatment for macular edema, at the 2025 IOIS Congress, aiming to better ...

The trial is evaluating KB803 for the treatment and prevention of corneal abrasions in dystrophic epidermolysis bullosa ...

Sanaregen Vision Therapeutics invites investors to reserve shares as it prepares for an equity crowdfunding campaign to advance retinal disease treatments.